Mirati Therapeutics Stock Defies Market Downturn with Unwavering Stability

In a trading session characterized by broad market weakness, Mirati Therapeutics shares demonstrated exceptional resilience. The stock held completely flat, a notable show of strength against a 0.5% decline in the S&P 500 index.

This stability appears deeply rooted in significant advancements within the company’s oncology pipeline, which may be insulating the stock from wider market volatility.

• Adagrasib (Krazati) Momentum: The KRAS G12C inhibitor continues to progress through clinical trials. Just two days ago, the Phase 2/3 KRYSTAL-7 study received an update as it evaluates Adagrasib’s potential as a promising therapeutic option.
• Strategic Pipeline Advancement: Under Bristol Myers Squibb, development continues on assets originally from Mirati. The PRMT5 inhibitor, BMS-986504,... Read more...